Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance

Leukemia Research

Volumn 39, Issue 12, 2015, Pages 1428-1436

  He, Yunhua ^a   Wang, Yuchan ^a   Liu, Hong ^b   Xu, Xiaohong ^b   He, Song ^b   Tang, Jie ^a   Huang, Yuejiao ^b   Miao, Xiaobing ^b   Wu, Yaxun ^b   Wang, Qiru ^a   Cheng, Chun ^a  

^a NANTONG MEDICAL COLLEGE   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

CAM DR; MAPK ERK; MM; PI3K Akt; PKM2; Proliferation

Indexed keywords

FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; CARRIER PROTEIN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TUMOR PROTEIN;

ARTICLE; BONE MARROW STROMA CELL; CANCER RESISTANCE; CELL ADHESION; CELL ADHESION MEDIATED DRUG RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BIOSYNTHESIS; CELL DIVISION; COCULTURE; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL LINE;

CARRIER PROTEINS; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STROMAL CELLS; THYROID HORMONES;

EID: 84961711621     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.09.019     Document Type: Article

References (38)

1. Anderson K.C., Carrasco R.D. Pathogenesis of myeloma. Annu. Rev. Pathol. 2011, 6:249-274.
2. Karadimitris A., et al. Myeloma propagating cells, drug resistance and relapse. Stem Cells 2015, Epub ahead of print.
3. Hideshima T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
4. Laubach J.P., et al. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms macroglobulinemia. Leuk. Lymphoma 2009, 50:694-702.
5. Kawano Y., et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 2015, 263:160-172.
6. Borsi E., et al. HIF-1alpha inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. Exp. Cell Res. 2014, 328:444-455.
7. Cohen K., et al. Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via alphavbeta3 integrin in myeloma cells. Oncotarget 2014, 5:6312-6322.
8. Steinbrunn T., et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 2011, 117:1998-2004.
9. Lunghi P., et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008, 112:2450-2462.
10. Wang M.C., Fu X.D., Li M.X. PI-3K/Akt/GSK-3beta signaling cascades stimulated by insulin like growth factor-I contribute to multiple myeloma cells proliferation and survival. Chin. Med. J. (Engl.) 2006, 119:1226-1229.
11. Goldberg M.S., Sharp P.A. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J. Exp. Med. 2012, 209:217-224.
12. Mazurek S., et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15:300-308.
13. Christofk H.R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
14. Spoden G.A., et al. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp. Cell Res. 2009, 315:2765-2774.
15. Qin X., et al. Activation of Akt protects cancer cells from growth inhibition induced by PKM2 knockdown. Cell Biosci. 2014, 4:20.
16. Feng J., et al. PKM2 gene regulates the behavior of pancreatic cancer cells via mitogen-activated protein kinase pathways. Mol. Med. Rep. 2015, 11:2111-2117.
17. Weinberger R., et al. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. Eur. J. Cancer Care (Engl.) 2007, 16:333-337.
18. Ahmed A.S., et al. M2-PK as a novel marker in ovarian cancer: a prospective cohort study. Eur. J. Gynaecol. Oncol. 2007, 28:83-88.
19. Schneider J. Tumor markers in detection of lung cancer. Adv. Clin. Chem. 2006, 42:1-41.
20. Wang Y., et al. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett. 2014, 343:6-13.
21. Sun Q., et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4129-4134.
22. Burger J.A., et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
23. Stetak A., et al. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007, 67:1602-1608.
24. Kurtova A.V., et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009, 113:4604-4613.
25. Lwin T., et al. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 2010, 116:5228-5236.
26. Pene F., et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002, 21:6587-6597.
27. Abdi J., et al. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis. PLoS One 2014, 9:e96608.
28. Richardson P.G., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl. J. Med. 2005, 352:2487-2498.
29. Azab F., et al. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. Br. J. Haematol. 2014, 165:89-101.
30. Damiano J.S., Hazlehurst L.A., Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001, 15:1232-1239.
31. Taylor S.T., Hickman J.A., Dive C. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J. Natl. Cancer Inst. 2000, 92:18-23.
32. Zhu J., et al. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma. Curr. Med. Chem. 2014, 21:3173-3187.
33. Chatterjee M., et al. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2013, 98:1132-1141.
34. Steinbrunn T., et al. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br. J. Haematol. 2012, 159:430-440.
35. Chatterjee M., et al. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004, 104:3712-3721.
36. Ma J., et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J. Clin. Invest. 2010, 120:103-114.
37. Belanger S., et al. Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells. Gynecol. Oncol. 2005, 97:796-806.
38. Wan C., et al. MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability. Oncogene 2015, 34:237-245.